Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia

Chiorazzi, 2005, Chronic lymphocytic leukemia, The New England Journal of Medicine, 352, 804, 10.1056/NEJMra041720 Rozman, 1995, Chronic lymphocytic leukemia, The New England Journal of Medicine, 333, 1052, 10.1056/NEJM199510193331606 Zwiebel, 1998, Chronic lymphocytic leukemia: staging and prognostic factors, Seminars in Oncology, 25, 42 Dighiero, 1998, Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia, The New England Journal of Medicine, 338, 1506, 10.1056/NEJM199805213382104 Binet, 1981, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis, Cancer, 48, 198, 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V Rai, 1975, Clinical staging of chronic lymphocytic leukemia, Blood, 46, 219, 10.1182/blood.V46.2.219.219 Montserrat, 1986, Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance, British Journal of Haematology, 62, 567, 10.1111/j.1365-2141.1986.tb02969.x Rozman, 1984, Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases, Blood, 64, 642, 10.1182/blood.V64.3.642.642 Di Giovanni, 1989, Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia, Acta Haematologica, 81, 181, 10.1159/000205558 Hallek, 1999, Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia, Blood, 93, 1732 Kallander, 1984, Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia, Cancer, 54, 2450, 10.1002/1097-0142(19841201)54:11<2450::AID-CNCR2820541123>3.0.CO;2-R Knauf, 1997, Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia, Leukemia & Lymphoma, 27, 523, 10.3109/10428199709058320 Krober, 2002, V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia, Blood, 100, 1410, 10.1182/blood.V100.4.1410.h81602001410_1410_1416 Crespo, 2003, ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia, The New England Journal of Medicine, 348, 1764, 10.1056/NEJMoa023143 Damle, 1999, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, 94, 1840, 10.1182/blood.V94.6.1840 Hamblin, 1999, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia, Blood, 94, 1848, 10.1182/blood.V94.6.1848 Lin, 2002, Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia, Blood, 100, 1404, 10.1182/blood-2001-11-0066 Orchard, 2004, ZAP-70 expression and prognosis in chronic lymphocytic leukemia, Lancet, 363, 105, 10.1016/S0140-6736(03)15260-9 Oscier, 2002, Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors, Blood, 100, 1177, 10.1182/blood.V100.4.1177.h81602001177_1177_1184 Rassenti, 2004, ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia, The New England Journal of Medicine, 351, 893, 10.1056/NEJMoa040857 Vasconcelos, 2003, Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia, Journal of Clinical Oncology, 21, 3928, 10.1200/JCO.2003.02.134 Dohner, 2000, Genomic aberrations and survival in chronic lymphocytic leukemia, The New England Journal of Medicine, 343, 1910, 10.1056/NEJM200012283432602 Mertens, 2006, Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism, Proceedings of the National Academy of Sciences of the United States of America, 103, 7741, 10.1073/pnas.0600494103 Dohner, 1997, 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis, Blood, 89, 2516, 10.1182/blood.V89.7.2516 Dohner, 1995, p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias, Blood, 85, 1580, 10.1182/blood.V85.6.1580.bloodjournal8561580 El Rouby, 1993, p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression, Blood, 82, 3452, 10.1182/blood.V82.11.3452.3452 Fenaux, 1992, Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis, Leukemia, 6, 246 Gaidano, 1991, p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia, Proceedings of the National Academy of Sciences of the United States of America, 88, 5413, 10.1073/pnas.88.12.5413 Kröber, 2000, Evaluation of the p53 mutation and deletion status in B-CLL demonstrates resistance to therapy in vivo and confirms prognostic impact, Blood, 96 Sturm, 2003, Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy, Cell Death and Differentiation, 10, 477, 10.1038/sj.cdd.4401194 Trbusek, 2006, Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment, Leukemia, 20, 1159, 10.1038/sj.leu.2404195 Lens, 1997, p53 abnormalities in B-cell prolymphocytic leukemia, Blood, 89, 2015, 10.1182/blood.V89.6.2015 Wattel, 1994, p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies, Blood, 84, 3148, 10.1182/blood.V84.9.3148.3148 Austen, 2005, Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL, Blood, 106, 3175, 10.1182/blood-2004-11-4516 Schaffner, 1999, Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia, Blood, 94, 748, 10.1182/blood.V94.2.748 Stankovic, 1999, Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukemia, Lancet, 353, 26, 10.1016/S0140-6736(98)10117-4 Bullrich, 1999, ATM mutations in B-cell chronic lymphocytic leukemia, Cancer Research, 59, 24 Krober, 2006, Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia, Journal of Clinical Oncology, 20, 969, 10.1200/JCO.2005.03.7184 Rosenwald, 2001, Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia, The Journal of Experimental Medicine, 194, 1639, 10.1084/jem.194.11.1639 Binet, 2006, International Workshop on Chronic Lymphocytic Leukemia (IWCLL). Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia, Blood, 107, 859, 10.1182/blood-2005-04-1677 Shanafelt, 2006, Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia, Journal of Clinical Oncology, 24, 4634, 10.1200/JCO.2006.06.9492 Stilgenbauer, 2002, VH mutation status and genomic aberrations in the prospective CLL1 trial (Binet A) of the German CLL Study Group (GCLLSG), Blood, 100, 168 Bergmann, 2003, Blood, 102 Eichhorst, 2006, Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia, Blood, 107, 885, 10.1182/blood-2005-06-2395 Deutsch Studiengruppe. http://dcllsg.de. Geisler, 1997, In B-cell chronic lymphocytic leukemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients, Leukemia Research, 21, 1011, 10.1016/S0145-2126(97)00095-7 Byrd, 2006, Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy, Journal of Clinical Oncology, 24, 437, 10.1200/JCO.2005.03.1021 Stilgenbauer, 2002, Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy, The New England Journal of Medicine, 347, 452, 10.1056/NEJM200208083470619 Lozanski, 2004, Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions, Blood, 103, 3278, 10.1182/blood-2003-10-3729 Pettitt, 2006, Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukemia patients with p53 defects, Leukemia, 20, 1441, 10.1038/sj.leu.2404265 Stilgenbauer, 2005, 17p deletion predicts for inferior overall survival after fludarabine – based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 Trial of the GCLLSG, Blood, 106, 715, 10.1182/blood.V106.11.715.715 Oscier, 2005, Prognostic Factors in the UK LRF CLL4 Trial, Blood, 106, 2099, 10.1182/blood.V106.11.2099.2099 Dreger, 2002, Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia, Leukemia, 16, 985, 10.1038/sj.leu.2402530 Zenz, 2006, Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia, Blood, 108, 2127, 10.1182/blood-2006-04-007898 Ritgen, 2003, Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia, Blood, 101, 2049, 10.1182/blood-2002-06-1744 Dreger, 2004, The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status, Blood, 103, 2850, 10.1182/blood-2003-05-1549 Ritgen, 2004, Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR, Blood, 104, 2600, 10.1182/blood-2003-12-4321 Moreno, 2005, Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia, Journal of Clinical Oncology, 23, 3433, 10.1200/JCO.2005.04.531 Sorror, 2005, Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia, Journal of Clinical Oncology, 23, 3819, 10.1200/JCO.2005.04.569 Gribben, 2005, Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia, Blood, 106, 4389, 10.1182/blood-2005-05-1778